**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 81585

**Manuscript Type:** LETTER TO THE EDITOR

**Timing of biliary decompression for acute cholangitis**

Yang J *et al*. Timing of biliary decompression for AC

Jian Yang, Ying Liu, Shi Liu

**Jian Yang, Shi Liu,** Central Laboratory, The Third Affiliated Hospital, Qiqihar Medical University, Qiqihar 161000, Heilongjiang Province, China

**Ying Liu,** Department of Medical Oncology, The Third Affiliated Hospital, Qiqihar Medical University, Qiqihar 161000, Heilongjiang Province, China

**Author contributions:** Yang J designed and wrote this report; Liu S gave guidance on article revision; Liu Y reviewed the literature and contributed to drafting the manuscript; All authors issued final approval for the version to be submitted.

**Corresponding author: Shi Liu, PhD, Chief Physician,** Central Laboratory, The Third Affiliated Hospital, Qiqihar Medical University, No. 27 Taishun Street, Tiefeng, Qiqihar 161000, Heilongjiang Province, China. shiliu2199@163.com

**Received:** November 16, 2022

**Revised:** January 3, 2023

**Accepted:** January 16, 2023

**Published online:** February 7, 2023

**Abstract**

Severe acute cholangitis (AC) exacerbates the risk of death because of the rapid progression of the disease. The optimal timing of biliary decompression (BD) as a necessary intervention in patients with severe AC is controversial. A recently report titled “Timing of endoscopic retrograde cholangiopancreatography in the treatment of acute cholangitis of different severity” in the *World Journal of Gastroenterology* that the optimal time of endoscopic retrograde cholangiopancreatography for treating patients with severe AC is ≤ 48 but not ≤ 24 h, providing clinical evidence for selecting the optimal time for implementation of BD. Here, we discuss the controversy over the optimal timing of BD for AC based on guidelines and clinical evidence, and consider that more high-level clinical researches are urgent needed to benefit the management of patients with different severity of AC.

**Key Words:** Acute cholangitis; Biliary decompression; Endoscopic retrograde cholangiopancreatography; Severity; Optimal time; Clinical evidence

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Yang J, Liu Y, Liu S. Timing of biliary decompression for acute cholangitis. *World J Gastroenterol* 2023; 29(5): 904-907

**URL:** https://www.wjgnet.com/1007-9327/full/v29/i5/904.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v29.i5.904

**Core Tip:** Severe acute cholangitis (AC) exacerbates the risk of death because of the rapid progression of the disease. The optimal timing of biliary decompression (BD) as an intervention for severe AC is controversial. The purpose of this letter is to highlight the controversy surrounding the existing clinical evidence regarding BD for the treatment of AC of varying severity and to suggest that clinical studies providing higher levels of evidence will improve the therapeutic benefits.

**TO THE EDITOR**

Acute cholangitis (AC) originates as an infection of the extrahepatic biliary system and is usually characterized by rapid progression leading to systemic sepsis. The morality rate of severe AC may reach 30%[1]. In most cases, biliary decompression (BD) is necessary to treat patients with severe AC, regardless of the treatment modality chosen [endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic biliary drainage, or stone removal][2]. However, the optimal time at which to implement BD to obtain the maximum therapeutic benefit for patients with AC remains uncertain.

We recently became extremely interested in a retrospective study by Huang *et al*[3] published in the October 2022 issue of the *World Journal of Gastroenterology*. This was a high-quality observational study with a Newcastle-Ottawa Quality Assessment Scale score of 7 (3, 2, 2)[4]. It was independently assessed by two of our authors, and disagreements were resolved by a third author. Based on a retrospective analysis of 683 patients with AC, the conclusions drawn by the authors properly summarize the data in the study. The authors’ data indicated that 30-d mortality in patients with AC was not significantly different between ERCP performed at > 24 and ≤ 24 h. However, patients with AC had lower 30-d mortality and a shorter length of stay when ERCP was performed at ≤ 48 h. Additionally, patients with grade III AC had lower 30-d mortality rates than patients with grade I and II AC, although they had higher intensive care unit admission rates and longer lengths of stay[3]. Huang *et al*[3] suggested that a ≤ 48-h duration from the patient’s presentation to initiation of ERCP therapy, rather than a ≤ 24-h duration, provided the best survival benefit for patients with AC, especially for patients with grade III AC. This unique insight breaks with the traditional treatment concept that earlier performance of BD is associated with better outcomes in patients with severe AC. We thank Huang *et al*[3] for their study, which provides clinical evidence for the optimal timing of BD in patients with grade III AC.

The 2018 revised Tokyo guideline (TG18) currently serves as the most influential guideline for assessing AC severity. It delineates three grades of assessment of AC severity and indicates that the impact of the BD implementation time on the therapeutic benefit is significantly correlated with AC severity[5]. Therefore, we consider that the AC severity characterizes the urgency of the BD implementation time.

Reference Citation Analysis (RCA) (https://www.referencecitationanalysis.com/) is an artificial intelligence technology-based open multidisciplinary citation analysis database. We searched the RCA database for articles in cutting-edge fields in the last 3 years using the search terms “endoscopic retrograde cholangiopancreatography”, “biliary decompression”, and “acute cholangitis”. Recent guidelines and clinical evidence suggest that the optimal timing of BD implementation remains controversial. First, controversy regarding the timing of BD implementation in the guideline exists primarily for patients with grade II and III AC. The American Society for Gastrointestinal Endoscopy (ASGE) 2021 guideline states that important outcome indicators for evaluating the survival benefit in patients with AC are 30-d mortality, inpatient mortality, length of stay, and organ failure[2]. The guideline also suggests that performance of ERCP at ≤ 48 h may be associated with lower 30-d mortality and a shorter length of stay[2]. However, the ASGE 2021 guideline does not report the correlation between the time to BD implementation and AC severity because the available clinical evidence is insufficient[2]. TG18 states that BD in patients with grade II AC should be performed within 24 h, and although clinical data do not indicate the optimal time for BD in patients with grade III AC, urgent decompression (within 24 h) may improve the prognosis of patients with grade III AC[5]. The European Society of Gastrointestinal Endoscopy 2019 guideline states that for patients with severe AC (grade III), implementation of BD is recommended within 12 h; for patients with moderate AC (grade II), it should be performed within 48 to 72 h[6]. Second, recent clinical studies have produced controversial results in terms of early implementation of BD for patients with grade III AC. In addition to the study by Huang *et al*[3] discussed herein (BD at ≤ 48 but not ≤ 24 h), another retrospective study by Lu *et al*[7]showed that BD is recommended at 24 h of admission for patients with grade III AC and within 12 h for those with AC accompanied by neurological or cardiovascular dysfunction. However, a study by Becq *et al*[8] using a propensity score matching approach indicated that the use of BD within 6h or 12 h of AC onset was not associated with better clinical outcomes, but possibly reduced readmission rates. Finally, the results of three recent systematic reviews and meta-analyses suggest that the controversy over the optimal timing of BD is mainly focused within 24 h and 48 h based on data analysis of superior outcomes within their respective time zones[9-11]. However, the three studies did not report that the optimal timing of BD affects survival outcomes in populations with different severities of AC (*i.e.*, grades I, II, and III)[9-11].

Based on the above-mentioned current controversies, we present the following future outlook. First, because of the controversy in the current guidelines and among recent clinical studies regarding the optimal timing of BD for patients with grade II and III AC, a multicenter prospective cohort study or randomized controlled trial should be conducted. Second, the medical community is called upon to pay attention to the clinical studies that have been reported and to perform systematic reviews and meta-analyses on the optimal time to implement BD for the treatment of patients with grade II and III AC.

In conclusion, a higher level of clinical evidence regarding the optimal time to implement BD in patients with different severities of AC is needed to improve the therapeutic benefit.

**REFERENCES**

1 **Lan Cheong Wah D**, Christophi C, Muralidharan V. Acute cholangitis: current concepts. *ANZ J Surg* 2017; **87**: 554-559 [PMID: 28337833 DOI: 10.1111/ans.13981]

2 **Buxbaum JL**, Buitrago C, Lee A, Elmunzer BJ, Riaz A, Ceppa EP, Al-Haddad M, Amateau SK, Calderwood AH, Fishman DS, Fujii-Lau LL, Jamil LH, Jue TL, Kwon RS, Law JK, Lee JK, Naveed M, Pawa S, Sawhney MS, Schilperoort H, Storm AC, Thosani NC, Qumseya BJ, Wani S. ASGE guideline on the management of cholangitis. *Gastrointest Endosc* 2021; **94**: 207-221.e14 [PMID: 34023065 DOI: 10.1016/j.gie.2020.12.032]

3 **Huang YC**, Wu CH, Lee MH, Wang SF, Tsou YK, Lin CH, Sung KF, Liu NJ. Timing of endoscopic retrograde cholangiopancreatography in the treatment of acute cholangitis of different severity. *World J Gastroenterol* 2022; **28**: 5602-5613 [PMID: 36304084 DOI: 10.3748/wjg.v28.i38.5602]

4 **Wells GA**, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [cited 18 August 2022]. Available from: https://www.ohri.ca//programs/clinical\_epidemiology/oxford.asp

5 **Kiriyama S**, Kozaka K, Takada T, Strasberg SM, Pitt HA, Gabata T, Hata J, Liau KH, Miura F, Horiguchi A, Liu KH, Su CH, Wada K, Jagannath P, Itoi T, Gouma DJ, Mori Y, Mukai S, Giménez ME, Huang WS, Kim MH, Okamoto K, Belli G, Dervenis C, Chan ACW, Lau WY, Endo I, Gomi H, Yoshida M, Mayumi T, Baron TH, de Santibañes E, Teoh AYB, Hwang TL, Ker CG, Chen MF, Han HS, Yoon YS, Choi IS, Yoon DS, Higuchi R, Kitano S, Inomata M, Deziel DJ, Jonas E, Hirata K, Sumiyama Y, Inui K, Yamamoto M. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). *J Hepatobiliary Pancreat Sci* 2018; **25**: 17-30 [PMID: 29032610 DOI: 10.1002/jhbp.512]

6 **Manes G**, Paspatis G, Aabakken L, Anderloni A, Arvanitakis M, Ah-Soune P, Barthet M, Domagk D, Dumonceau JM, Gigot JF, Hritz I, Karamanolis G, Laghi A, Mariani A, Paraskeva K, Pohl J, Ponchon T, Swahn F, Ter Steege RWF, Tringali A, Vezakis A, Williams EJ, van Hooft JE. Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. *Endoscopy* 2019; **51**: 472-491 [PMID: 30943551 DOI: 10.1055/a-0862-0346]

7 **Lu ZQ**, Zhang HY, Su CF, Xing YY, Wang GX, Li CS. Optimal timing of biliary drainage based on the severity of acute cholangitis: A single-center retrospective cohort study. *World J Gastroenterol* 2022; **28**: 3934-3945 [PMID: 36157549 DOI: 10.3748/wjg.v28.i29.3934]

8 **Becq A**, Chandnani M, Bartley A, Nuzzo A, Bilal M, Bharadwaj S, Cohen J, Gabr M, Berzin TM, Pleskow DK, Sawhney MS. ERCP within 6 or 12 h for acute cholangitis: a propensity score-matched analysis. *Surg Endosc* 2022; **36**: 2418-2429 [PMID: 33977378 DOI: 10.1007/s00464-021-08523-w]

9 **Du L**, Cen M, Zheng X, Luo L, Siddiqui A, Kim JJ. Timing of Performing Endoscopic Retrograde Cholangiopancreatography and Inpatient Mortality in Acute Cholangitis: A Systematic Review and Meta-Analysis. *Clin Transl Gastroenterol* 2020; **11**: e00158 [PMID: 32352721 DOI: 10.14309/ctg.0000000000000158]

10 **Iqbal U**, Khara HS, Hu Y, Khan MA, Ovalle A, Siddique O, Sun H, Shellenberger MJ. Emergent versus urgent ERCP in acute cholangitis: a systematic review and meta-analysis. *Gastrointest Endosc* 2020; **91**: 753-760.e4 [PMID: 31628955 DOI: 10.1016/j.gie.2019.09.040]

11 **Lyu Y**, Wang B, Ye S, Cheng Y. Impact of the Timing of Endoscopic Retrograde Cholangiopancreatography for the Treatment of Acute Cholangitis: A Meta-analysis and Systematic Review. *Surg Laparosc Endosc Percutan Tech* 2022; **32**: 764-769 [PMID: 36223305 DOI: 10.1097/SLE.0000000000001110]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 16, 2022

**First decision:** January 2, 2023

**Article in press:** January 16, 2023

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Isogai M, Japan; Kimura Y, Japan **S-Editor:** Zhang H **L-Editor:** A **P-Editor:** Zhang H



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**